Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 247
Tipo Título / Nombre Autor(es) Año
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P, CETLAM and PETHEMA groups 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, Barba P, Vives S, González-Campos J, Tormo M, Esteve J, López A, Moreno MJ, Ribera J, Alonso N, Bermúdez A, Amigo ML, Genescà E, García D, Vall-Llovera F, Bergua JM, Guàrdia R, Monteserín MC, Bernal T, Calbacho M, Martínez MP, Feliu E, PETHEMA Group 2018
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A, PETHEMA Group, Spanish Society of Hematology 2018
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail NS, Podoltsev NA, Brummer AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow MR, Tathi AT, Perreault S, Kon Kim T, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore S, Zeidan, AM 2017
Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail NS, Podoltsev NA, Fathi AT, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Brunner AM, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kon Kim T, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore S, Zeidan, AM 2017
Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genesca E, Martínez-Carballeira D, Martino R, Vives S, Guàrdia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sánchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Ribera JM 2017
Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, Bergua J, Pérez de Oteyza J, Serrano J, Gorrochategui J, Vicente ML, Martínez Cuadron D, Montesinos P, Martínez López J, Ballesteros J 2017
Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) Ribera JM, Morgades M, Montesinos P, Martínez-Carballeira D, Gil C, Barba P, Tormo M, García-Boyero R, Guàrdia R, Pedreño M, Mercadal S, Novo A, Hernández-Rivas JM, Bergua J, González-Campos J, Amigo ML, Cervera M, Martínez-Sánchez P, Martino R, Calbacho M, García-Guiñon A, Vives S, Feliu E, Orfao A 2017
Lenalidomida en combinación con R-ESHAP en pacientes con linfoma difuso de células B grandes (LDCBG) refractorio o en recaída: estudio fase 2 del Grupo Español Geltamo Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, González Barca E, Salar A, Espeso M, Grande C, Bergua J, Montes Moreno S, López Guillermo A, Campo E, Caballero D, Martín AÁ 2017
Nuevo modelo para cuantificar la actividad farmacológica in vitro de anticuerpos biespecíficos en hemopatías maliganas Primo D, Martínez Cuadrón D, Montesinos P, De la Serna J, Ribera JM, Vives S, Bergua J, Pérez de Oteyza J, Serrano J, &10, Gorrochategui J, Vicente ML, Gómez C, Martínez López J, &10, Hernández P, Ballesteros J 2017